Goldman is interested in cell genesis and regeneration in the adult brain, with a focus on the use of neural and glial progenitor cells in both modeling and treating the neurodegenerative and myelin diseases. His group is especially interested in the contribution of glial pathology to neurological disease, and in the therapeutic potential of glial-directed treatment strategies. He remains active clinically, and is additionally board-certified in neuro-oncology.

Goldman has published over 250 papers in his field, including over 30 US patents. He is a recipient of the NIH’s Jacob Javits Neuroscience Award and the Novo Nordisk Foundation Laureate Award, and has been elected to Academia Europaea, the Association of American Physicians, the American Society for Clinical Investigation, and is a Fellow of the American Neurological Association. He has served as a permanent member of the FDA CTAG Advisory Committee, and is a co-founder of Lyrik Therapeutics and the Oscine Corporation; the latter is now a part of Sana Biotechnology, where Goldman leads its CNS therapy program. His current work is supported by NINDS, NIDA, NIA, NIMH, the Adelson Medical Research Foundation, Lyrik and Sana in the US, and by the Olav Thon, Lundbeck and Novo Nordisk Foundations in Denmark.